US Bancorp DE Sells 3,228 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

US Bancorp DE trimmed its position in CRISPR Therapeutics AG (NASDAQ:CRSP) by 55.5% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,589 shares of the company’s stock after selling 3,228 shares during the period. US Bancorp DE’s holdings in CRISPR Therapeutics were worth $122,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. ProShare Advisors LLC raised its holdings in CRISPR Therapeutics by 10.1% during the first quarter. ProShare Advisors LLC now owns 5,791 shares of the company’s stock worth $395,000 after buying an additional 530 shares during the last quarter. Blair William & Co. IL raised its holdings in shares of CRISPR Therapeutics by 8.2% in the 1st quarter. Blair William & Co. IL now owns 147,890 shares of the company’s stock worth $10,080,000 after acquiring an additional 11,190 shares during the last quarter. Vanguard Group Inc. lifted its position in CRISPR Therapeutics by 2.9% in the 1st quarter. Vanguard Group Inc. now owns 1,636,799 shares of the company’s stock valued at $111,564,000 after acquiring an additional 46,148 shares in the last quarter. Orion Capital Management LLC boosted its stake in CRISPR Therapeutics by 44.0% during the 1st quarter. Orion Capital Management LLC now owns 720 shares of the company’s stock valued at $49,000 after purchasing an additional 220 shares during the last quarter. Finally, SR One Capital Management LP bought a new stake in CRISPR Therapeutics during the 1st quarter worth approximately $71,496,000. 69.20% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

CRSP has been the topic of a number of analyst reports. Rodman & Renshaw started coverage on shares of CRISPR Therapeutics in a report on Friday, August 2nd. They set a “buy” rating and a $90.00 price objective on the stock. Stifel Nicolaus cut their price target on shares of CRISPR Therapeutics from $60.00 to $59.00 and set a “hold” rating on the stock in a report on Tuesday, August 6th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $53.00 price objective on shares of CRISPR Therapeutics in a research note on Wednesday, November 6th. Chardan Capital cut their target price on CRISPR Therapeutics from $112.00 to $94.00 and set a “buy” rating on the stock in a research note on Tuesday, August 6th. Finally, Barclays decreased their price target on CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating for the company in a research report on Wednesday, November 6th. Three investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $74.94.

Insider Buying and Selling

In related news, CEO Samarth Kulkarni sold 30,000 shares of the firm’s stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $55.62, for a total transaction of $1,668,600.00. Following the completion of the transaction, the chief executive officer now owns 196,540 shares of the company’s stock, valued at $10,931,554.80. This trade represents a 13.24 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, General Counsel James R. Kasinger sold 1,089 shares of the company’s stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $46.28, for a total transaction of $50,398.92. Following the completion of the transaction, the general counsel now owns 62,597 shares in the company, valued at approximately $2,896,989.16. The trade was a 1.71 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 35,382 shares of company stock valued at $1,917,679 over the last quarter. Corporate insiders own 4.10% of the company’s stock.

CRISPR Therapeutics Stock Up 0.9 %

CRISPR Therapeutics stock opened at $47.25 on Friday. The firm has a fifty day simple moving average of $47.88 and a two-hundred day simple moving average of $52.04. CRISPR Therapeutics AG has a twelve month low of $43.42 and a twelve month high of $91.10. The company has a market capitalization of $4.03 billion, a PE ratio of -16.70 and a beta of 1.67.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.42) by $0.41. The company had revenue of $0.60 million during the quarter, compared to analyst estimates of $6.65 million. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. During the same period in the prior year, the business posted ($1.41) earnings per share. As a group, equities analysts expect that CRISPR Therapeutics AG will post -5.2 earnings per share for the current fiscal year.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.